0001104659-21-130030.txt : 20211026 0001104659-21-130030.hdr.sgml : 20211026 20211026170633 ACCESSION NUMBER: 0001104659-21-130030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211026 FILED AS OF DATE: 20211026 DATE AS OF CHANGE: 20211026 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Merck KGaA CENTRAL INDEX KEY: 0001764133 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40925 FILM NUMBER: 211349473 BUSINESS ADDRESS: STREET 1: FRANKFURTER STR. 250 CITY: DARMSTADT STATE: 2M ZIP: 64293 BUSINESS PHONE: 004961517245950 MAIL ADDRESS: STREET 1: FRANKFURTER STR. 250 CITY: DARMSTADT STATE: 2M ZIP: 64293 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xilio Therapeutics, Inc. CENTRAL INDEX KEY: 0001840233 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851623397 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-833-1027 MAIL ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 4 1 tm2130646-26_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-10-26 1 0001840233 Xilio Therapeutics, Inc. XLO 0001764133 Merck KGaA FRANKFURTER STRASSE 250 DARMSTADT 2M 64293 GERMANY 0 0 1 0 Common Stock 2021-10-26 4 C 0 416060 A 416060 I See Footnote Common Stock 2021-10-26 4 C 0 264765 A 680825 I See Footnote Series B Preferred Stock 2021-10-26 4 C 0 3952568 D Common Stock 416060 0 I See Footnote Series C Preferred Srock 2021-10-26 4 C 0 2515271 D Common Stock 264765 0 I See Footnote The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V. The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. /s/ Christian Uhrich, Authorized signatory of Merck KGaA, Darmstadt, Germany 2021-10-26 /s/ Dariush Bahreini, Authorized signatory of Merck KGaA, Darmstadt, Germany 2021-10-26